The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 trial of lisocabtagene maraleucel for minimal residual disease in patients with large B-cell lymphoma.
 
Dai Chihara
Honoraria - AstraZeneca/Daiichi Sankyo
Consulting or Advisory Role - ADC Therapeutics; Genmab; Regeneron
Research Funding - Bristol-Myers Squibb/Celgene; Genentech (Inst); Genmab (Inst); Ono Pharmaceutical (Inst)
 
Ruitao Lin
Consulting or Advisory Role - ITM Oncologics; Lilly; Merck Sharp & Dohme, LLC; Monte Rosa Therapeutics
 
Alexander Boardman
No Relationships to Disclose
 
Ryan Lynch
Honoraria - Merck
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Foresight Diagnostics; Genentech; Janssen; SeaGen
Research Funding - Allogene Therapeutics; Bayer; Cyteir; Genentech; Incyte; Janssen Oncology; Merck; RAPT Therapeutics; Seagen; TG Therapeutics
 
David Kurtz
Employment - Foresight Diagnostics
Leadership - Foresight Diagnostics
Stock and Other Ownership Interests - Foresight Diagnostics
Patents, Royalties, Other Intellectual Property - Foresight Diagnostics
 
Mazyar Shadman
Employment - Bristol-Myers Squibb (I)
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Ascentage Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Fate therapeutics; Genentech; Genmab; Johnson & Johnson/Janssen; Kite, a Gilead company; Lilly; Merck; MorphoSys; Nurix; Pierre Fabre
Research Funding - Abbvie (Inst); AstraZeneca; BeiGene (Inst); Bristol-Myers Squibb/Celgene; Genentech (Inst); Genmab (Inst); Merck (Inst); Nurix; Sana Biotechnology
Patents, Royalties, Other Intellectual Property - Koi Biotherapeutics (Stock options); Koi Biotherapeutics Stock options
 
Alex Herrera
Consulting or Advisory Role - Abbvie; Alimera Sciences; Bristol-Myers Squibb; Genentech/Roche; Genmab; Merck; Pfizer; Seagen; Takeda
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Kite, a Gilead company (Inst); Merck (Inst); Seagen (Inst)
 
Jeremy Abramson
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Alimera Sciences; AstraZeneca; BeiGene; Bluebird Bio; Bristol-Myers Squibb; C4 Therapeutics; Caribou Biosciences; Celgene; Cellectar; Century Therapeutics; EMD Serono; Epizyme; Foresight Diagnostics; Genmab; Gilead Sciences; Incyte; Interius Biotherapeutics; Janssen; Johnson & Johnson; Karyopharm Therapeutics; Kite, a Gilead company; Kymera; Lilly; Miltenyi Biotec; MorphoSys; MorphoSys; MustangBio; Novartis; Ono Pharmaceutical; Roche/Genentech; Seagen; Takeda
Research Funding - Alimera Sciences (Inst); Bristol-Myers Squibb/Celgene (Inst); Cellectis (Inst); Genentech (Inst); Merck (Inst); MustangBio (Inst); Regeneron (Inst); Seagen (Inst); Takeda (Inst)
 
Gilles Salles
Stock and Other Ownership Interests - Owkin
Consulting or Advisory Role - Abbvie; BeiGene; BeOne; BMS; Ellipses Pharma; Genmab; GlaxoSmithKline; Incyte; Ipsen; Janssen; Kite/Gilead; Loxo/Lilly; Merck; Novartis; Pfizer; Roche/Genentech
Research Funding - Abbvie (Inst); Genentech (Inst); Genmab (Inst); Ipsen (Inst); Janssen (Inst); nurix (Inst)
 
Jason Westin
Consulting or Advisory Role - Abbvie; Abbvie; ADC Therapeutics; Allogene Therapeutics; AstraZeneca; Bristol-Myers Squibb/Celgene/Juno; Chugai Pharma; Genentech/Roche; Genmab; Janssen Scientific Affairs; Kite/Gilead; Lyell Immunopharma; Merck; MorphoSys/Incyte; Novartis; Nurix; Regeneron; Seagen
Research Funding - ADC Therapeutics; Allogene Therapeutics; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Janssen; Kite/Gilead; MorphoSys/Incyte; Novartis; Nurix